Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
BrdU (5-Bromo-2′-deoxyuridine) (HB0979)
Description:Thymidine analog. Widely used to identify proliferating cells, enhances Yamanaka factor reprogramming
Purity:>98%
Rapamycin (HB2779)
Description:mTOR inhibitor and potent immunosuppressant. Also used in inducible gene editing methods (e.g. CRISPR/Cas9) and promotes hPSC differentiation.
Purity:>98%